REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 27th, 2005 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research • New York
This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 21st day of April, 2005, by and among Genaissance Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Note and Warrant Purchase Agreement, dated April 21, 2005, by and among the Company and the Investors (the “Purchase Agreement”). Capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Purchase Agreement.
SECURITY AGREEMENTSecurity Agreement • April 27th, 2005 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research • New York
THIS SECURITY AGREEMENT (this “Agreement”) is made as of April 21, 2005, by and among GENAISSANCE PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and the Investors set forth on the signatures page affixed hereto (each an “Investor” and collectively, the “Investors”).
PLEDGE AND SECURITY AGREEMENTPledge and Security Agreement • April 27th, 2005 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research • New York
WHEREAS, pursuant to that certain Note and Warrant Purchase Agreement, dated as of even date hereof (the “Purchase Agreement”), by and among the Pledgor, Lark Technologies, Inc. (“Lark”) and the Lenders, the Lenders have agreed to lend the Pledgor and Lark the sum of $4,500,000 (the “Loan”), which Loan is to be evidenced by senior secured promissory notes due 2007 (the “Notes”) issued by the Pledgor and Lark to the Lenders in the aggregate principal amount of the Loan; and
NOTE AND WARRANT PURCHASE AGREEMENT among GENAISSANCE PHARMACEUTICALS, INC., LARK TECHNOLOGIES, INC., the Co-Borrowers, and XMARK OPPORTUNITY FUND, L.P., XMARK OPPORTUNITY FUND, LTD., and XMARK JV INVESTMENT PARTNERS, LLC, the Purchasers Dated: April...Note and Warrant Purchase Agreement • April 27th, 2005 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research • New York
THIS NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April 21, 2005, by and among Genaissance Pharmaceuticals, Inc., a Delaware corporation (“Genaissance”) and Lark Technologies, Inc., a Delaware corporation (“Lark”, and together with Genaissance, the “Co-Borrowers”), and Xmark Opportunity Fund, Ltd., a Cayman Islands exempted company, Xmark Opportunity Fund, L.P., a Delaware limited partnership, and Xmark JV Investment Partners, LLC, a Delaware limited liability company (together, the “Purchasers” and each, a “Purchaser”).
